Apogee Therapeutics shares are trading higher after the company announced 52-week maintenance data from Part A of its Phase 2 APEX clinical trial of zumilokibart, a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis.